Global competition for China’s biotechnology innovations is entering a more aggressive phase as venture capital firms increasingly shift their focus toward early stage scientific research rather than waiting for assets to reach commercialization. Investors, particularly from the United States, are embedding themselves directly
Hong Kong based CK Life Sciences is preparing to advance its cancer vaccine pipeline into mainland China using a faster clinical development pathway as the country expands support for early stage drug innovation. Backed by the business empire of Li Ka-shing, the company
China’s contract drug manufacturing industry is facing growing uncertainty as United States pharmaceutical companies accelerate efforts to bring production back onshore and restructure global supply chains. The shift reflects broader geopolitical tensions and strategic concerns around dependency on overseas manufacturing, particularly in critical
China’s biotechnology sector has recorded a sharp rise in international licensing deals during the opening months of 2026, highlighting the country’s growing influence in global pharmaceutical research and drug development. The total value of outlicensing agreements signed by Chinese biotech companies in the
Chinese artificial intelligence driven drug discovery firm XtalPi Holdings has projected its first full year profit following a sharp rise in revenue, signaling growing commercial traction for AI powered pharmaceutical research in China. The Shenzhen based company said it expects to report a
China’s biotechnology sector is entering a new phase of financial maturity as companies move beyond heavy reliance on licensing agreements and tap deeper pools of domestic and international capital. Strong equity market performance, regulatory reforms and expanding innovation pipelines are reshaping the funding
China’s accelerating biotechnology expansion is driving an unexpected cost surge in one of the industry’s most critical research resources, laboratory monkeys used in preclinical drug testing. Prices for experimental monkeys have climbed to around 140,000 yuan per animal, a level that now exceeds
China’s biotechnology sector is on track for another record year in licensing activity as global pharmaceutical companies intensify their search for innovative drug candidates to offset looming patent expirations and rising research costs. Data from industry tracker Pharmcube shows that out licensing deals
China could become one of the first countries globally to approve a drug entirely designed by artificial intelligence, signalling a major shift in how new medicines are discovered and developed. Pharmaceutical executives say advances in AI and human genetics are accelerating China’s transition
China’s cell therapy sector is drawing renewed investor interest as NewCure Biotech raised more than 200 million yuan, or about $28 million, in a Series B financing round to accelerate development of its TCR T pipeline targeting solid tumors. The round was co
